person · Reporting owner
Szekeres David Leslie
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Connect Biopharma Holdings LtdCNTB · Entity 6516 | President | March 16, 2026 | March 16, 2026 |
| GRI Bio, Inc.GRI · Entity 8336 | Director | September 18, 2025 | September 22, 2025 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | EVP, Chief Operating Officer | July 13, 2023 | July 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Connect Biopharma Holdings Ltd
Report date March 16, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 215,739 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 215,739 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2034-06-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2034-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.
F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.
GRI Bio, Inc.
Report date September 18, 2025 · Filed September 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2035-09-18 | Direct | 39,897 |
Reported balance
After 2025-09-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-18 · Grant · Acquired 39,897 · Balance 39,897 F1: Options to purchase 29,293 shares vested in full upon the date of grant and options to purchase 9,974 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 29,293 shares vested in full upon the date of grant and options to purchase 9,974 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.
HERON THERAPEUTICS, INC. /DE/
Report date July 13, 2023 · Filed July 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,754 |
Ending reported balance
After 2023-07-13 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-07-13 · Exercise / conversion · Acquired 1,250 · Balance 31,202 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2023-07-13 · Exercise / conversion · Acquired 4,564 · Balance 35,766 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 3 · 2023-07-13 · Tax withholding · Disposed 2,012 · Balance 33,754 F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,250 |
Reported balance
After 2023-07-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-13 · Exercise / conversion · Disposed 1,250 · Balance 6,250 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,372 |
Reported balance
After 2023-07-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-13 · Exercise / conversion · Disposed 4,564 · Balance 23,372 F1: Restricted stock units convert into common stock on a one-for-one basis. F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2025 Filed Sep 22, 2025 16:06 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 39,897 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001602459-25-000004 · wk-form4_1758571561.xml · derivative · entry 1 Szekeres David Leslie · CIK 0001602459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,897 Underlying: Common Stock · 39,897 shares Expires 2035-09-18 F1 · derivative.exercise_date: Options to purchase 29,293 shares vested in full upon the date of grant and options to purchase 9,974 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 08:25 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 10,276 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001824293-25-000143 · wk-form4_1756297514.xml · derivative · entry 1 Szekeres David Leslie · CIK 0001602459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,276 Underlying: Common Stock · 10,276 shares Expires 2035-08-26 F1 · derivative.exercise_date: Options to purchase 6,933 shares vested in full upon the date of grant and options to purchase 3,343 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 16:58 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 7,545 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001824293-25-000116 · wk-form4_1755205093.xml · derivative · entry 1 Szekeres David Leslie · CIK 0001602459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,545 Underlying: Common Stock · 7,545 shares Expires 2035-08-13 F1 · derivative.exercise_date: The stock option vests in 4 equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 17:57 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 51,937 | $0.69 Strike: $0.69 | $35,613.20 |
DisclosureSEC source: 0001824293-25-000030 · wk-form4_1737759448.xml · derivative · entry 1 Szekeres David Leslie · CIK 0001602459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,937 Underlying: Common Stock · 51,937 shares Expires 2035-01-23 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 16:10 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 34,483 | $2.90 Strike: $2.90 | $100,000.70 |
DisclosureSEC source: 0001824293-23-000156 · wk-form4_1692043784.xml · derivative · entry 1 Szekeres David Leslie · CIK 0001602459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,483 Underlying: Common Stock · 34,483 shares Expires 2033-08-10 F1 · derivative.exercise_date: Vests as to 1/12th of the underlying shares of common stock on the date of grant, then in 11 equal quarterly installments such that the stock option is fully vested on the third annual anniversary of the date of grant. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 21:51 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042480 · doc4.xml · derivative · entry 5 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,372 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 21:51 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042480 · doc4.xml · derivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 21:51 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $1.31 | $2,635.72 |
DisclosureSEC source: 0001209191-23-042480 · doc4.xml · nonDerivative · entry 3 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,754 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 21:51 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-042480 · doc4.xml · nonDerivative · entry 2 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 21:51 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-042480 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:28 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024500 · doc4.xml · derivative · entry 5 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,936 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:28 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024500 · doc4.xml · derivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:28 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $2.88 | $5,794.56 |
DisclosureSEC source: 0001209191-23-024500 · doc4.xml · nonDerivative · entry 3 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,952 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:28 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024500 · doc4.xml · nonDerivative · entry 2 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:28 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024500 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 22:10 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantPerformance Stock Units · Derivative | 49,788 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004304 · doc4.xml · derivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,788 Underlying: Common Stock · 49,788 shares Expires not disclosed F1 · derivative.exercise_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested. F1 · derivative.expiration_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003564 · doc4.xml · derivative · entry 6 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003564 · doc4.xml · derivative · entry 5 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $3.17 | $6,378.04 |
DisclosureSEC source: 0001209191-23-003564 · doc4.xml · nonDerivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,150 F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-003564 · doc4.xml · nonDerivative · entry 3 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-003564 · doc4.xml · nonDerivative · entry 2 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 31, 2022 Filed Jan 17, 2023 22:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 1,654 | $3.27 | $5,412.72 |
DisclosureSEC source: 0001209191-23-003564 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,348 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2022. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053836 · doc4.xml · derivative · entry 5 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,064 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053836 · doc4.xml · derivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $3.76 | $7,565.12 |
DisclosureSEC source: 0001209191-22-053836 · doc4.xml · nonDerivative · entry 3 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,694 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053836 · doc4.xml · nonDerivative · entry 2 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053836 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 165,961 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-22-043292 · doc4.xml · derivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,961 Underlying: Common Stock · 165,961 shares Expires 2032-07-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 8 equal quarterly installments beginning one quarter after the date of grant (07/25/2022). Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:58 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042263 · doc4.xml · derivative · entry 6 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,628 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:58 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042263 · doc4.xml · derivative · entry 5 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:58 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $3.01 | $6,056.12 |
DisclosureSEC source: 0001209191-22-042263 · doc4.xml · nonDerivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,892 F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:58 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-042263 · doc4.xml · nonDerivative · entry 3 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:58 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-042263 · doc4.xml · nonDerivative · entry 2 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 29, 2022 Filed Jul 15, 2022 20:58 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 1,505 | $3.84 | $5,782.21 |
DisclosureSEC source: 0001209191-22-042263 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,090 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 29, 2022. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024523 · doc4.xml · derivative · entry 5 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,192 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024523 · doc4.xml · derivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $6.07 | $12,212.84 |
DisclosureSEC source: 0001209191-22-024523 · doc4.xml · nonDerivative · entry 3 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,585 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-024523 · doc4.xml · nonDerivative · entry 2 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-024523 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:09 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003364 · doc4.xml · derivative · entry 5 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,756 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:09 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003364 · doc4.xml · derivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:09 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $8.30 | $16,699.60 |
DisclosureSEC source: 0001209191-22-003364 · doc4.xml · nonDerivative · entry 3 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,783 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:09 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003364 · doc4.xml · nonDerivative · entry 2 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:09 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003364 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:26 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 55,320 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060553 · doc4.xml · derivative · entry 5 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,320 Underlying: Common Stock · 55,320 shares Expires not disclosed F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:26 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 92,200 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001209191-21-060553 · doc4.xml · derivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,200 Underlying: Common Stock · 92,200 shares Expires 2031-10-13 F4 · derivative.exercise_date: The stock option vests and becomes exercisable monthly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that the stock option will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:26 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060553 · doc4.xml · derivative · entry 3 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:26 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 433 | $10.55 | $4,568.15 |
DisclosureSEC source: 0001209191-21-060553 · doc4.xml · nonDerivative · entry 2 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,981 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:26 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060553 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:52 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046791 · doc4.xml · derivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.